Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Neurological Medicine
Volume 2017 (2017), Article ID 5146723, 3 pages
https://doi.org/10.1155/2017/5146723
Case Report

Levodopa Responsive Parkinsonism in Patients with Hemochromatosis: Case Presentation and Literature Review

1Department of Neurology, Henry Ford Hospital, Detroit, MI, USA
2Department of Neurology and Ophthalmology, Michigan State University, East Lansing, MI, USA

Correspondence should be addressed to Abhimanyu Mahajan; gro.shfh@1ajahama

Received 28 December 2016; Accepted 19 March 2017; Published 23 March 2017

Academic Editor: Norman S. Litofsky

Copyright © 2017 Tarun Girotra et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. E. Fleming and W. S. Sly, “Mechanisms of iron accumulation in hereditary hemochromatosis,” Annual Review of Physiology, vol. 64, pp. 663–680, 2002. View at Publisher · View at Google Scholar · View at Scopus
  2. J. L. Beard, J. R. Connor, and B. C. Jones, “Iron in the brain,” Nutrition Reviews, vol. 51, no. 6, pp. 157–170, 1993. View at Google Scholar · View at Scopus
  3. G. A. Salvador, “Iron in neuronal function and dysfunction,” BioFactors, vol. 36, no. 2, pp. 103–110, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. B. Halliwell, “Reactive oxygen species and the central nervous system,” Journal of Neurochemistry, vol. 59, no. 5, pp. 1609–1623, 1992. View at Publisher · View at Google Scholar · View at Scopus
  5. S. Parkkila, O. Niemela, R. S. Britton et al., “Molecular aspects of iron absorption and HFE expression,” Gastroenterology, vol. 121, no. 6, pp. 1489–1496, 2001. View at Publisher · View at Google Scholar · View at Scopus
  6. J. R. Connor, E. A. Milward, S. Moalem et al., “Is hemochromatosis a risk factor for Alzheimer's Disease?” Journal of Alzheimer's Disease, vol. 3, no. 5, pp. 471–477, 2001. View at Google Scholar · View at Scopus
  7. J. M. Bastin, M. Jones, C. A. O'Callaghan, L. Schimanski, D. Y. Mason, and A. R. M. Townsend, “Kupffer cell staining by an HFE-specific monoclonal antibody: implications for hereditary haemochromatosis,” British Journal of Haematology, vol. 103, no. 4, pp. 931–941, 1998. View at Publisher · View at Google Scholar · View at Scopus
  8. L. Zecca, M. B. H. Youdim, P. Riederer, J. R. Connor, and R. R. Crichton, “Iron, brain ageing and neurodegenerative disorders,” Nature Reviews Neuroscience, vol. 5, no. 11, pp. 863–873, 2004. View at Publisher · View at Google Scholar · View at Scopus
  9. S. Altamura and M. U. Muckenthaler, “Iron toxicity in diseases of aging: Alzheimer's disease, Parkinson's disease and atherosclerosis,” Journal of Alzheimer's Disease, vol. 16, no. 4, pp. 879–895, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. A. M. Snyder and J. R. Connor, “Iron, the substantia nigra and related neurological disorders,” Biochimica et Biophysica Acta (BBA)—General Subjects, vol. 1790, no. 7, pp. 606–614, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. S. Altamura and M. U. Muckenthaler, “Iron toxicity in diseases of aging: Alzheimer's disease, Parkinson's disease and atherosclerosis,” Journal of Alzheimer's Disease, vol. 16, no. 4, pp. 879–895, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. D. J. Costello, S. L. Walsh, H. J. Harrington, and C. H. Walsh, “Concurrent hereditary haemochromatosis and idiopathic Parkinson's disease: a case report series,” Journal of Neurology, Neurosurgery and Psychiatry, vol. 75, no. 4, pp. 631–633, 2004. View at Publisher · View at Google Scholar · View at Scopus
  13. J. E. Nielsen, L. N. Jensen, and K. Krabbe, “Hereditary haemochromatosis: a case of iron accumulation in the basal ganglia associated with a parkinsonian syndrome,” Journal of Neurology, Neurosurgery and Psychiatry, vol. 59, no. 3, pp. 318–321, 1995. View at Publisher · View at Google Scholar · View at Scopus
  14. A. H. Aamodt, L. J. Stovner, K. Thorstensen, S. Lydersen, L. R. White, and J. O. Aasly, “Prevalence of haemochromatosis gene mutations in Parkinson's disease,” Journal of Neurology, Neurosurgery and Psychiatry, vol. 78, no. 3, pp. 315–317, 2007. View at Publisher · View at Google Scholar · View at Scopus
  15. V. Greco, E. V. De Marco, F. E. Rocca et al., “Association study between four polymorphisms in the HFE, TF and TFR genes and Parkinson's disease in Southern Italy,” Neurological Sciences, vol. 32, no. 3, pp. 525–527, 2011. View at Publisher · View at Google Scholar · View at Scopus
  16. G. Biasiotto, S. Goldwurm, D. Finazzi et al., “HFE gene mutations in a population of Italian Parkinson's disease patients,” Parkinsonism and Related Disorders, vol. 14, no. 5, pp. 426–430, 2008. View at Publisher · View at Google Scholar · View at Scopus
  17. M. C. J. Dekker, P. C. Giesbergen, O. T. Njajou et al., “Mutations in the hemochromatosis gene (HFE), Parkinson's disease and parkinsonism,” Neuroscience Letters, vol. 348, no. 2, pp. 117–119, 2003. View at Publisher · View at Google Scholar · View at Scopus
  18. R. J. Guerreiro, J. M. Bras, I. Santana et al., “Association of HFE common mutations with Parkinson's disease, Alzheimer's disease and mild cognitive impairment in a Portuguese cohort,” BMC Neurology, vol. 6, article 24, 2006. View at Publisher · View at Google Scholar · View at Scopus
  19. D. D. Buchanan, P. A. Silburn, J. B. Chalk, D. G. Le Couteur, and G. D. Mellick, “The Cys282Tyr polymorphism in the HFE gene in Australian Parkinson's disease patients,” Neuroscience Letters, vol. 327, no. 2, pp. 91–94, 2002. View at Publisher · View at Google Scholar · View at Scopus